News

Retina-specific laminin-based generation of photoreceptor progenitors from human pluripotent stem cells under xeno-free and chemically defined conditions – now available in nature protocols

Stockholm 25th of February 2025 – The group of Dr. Hwee Goon Tay (scientific co-founder of Alder Therapeutics) at the Centre for Vision Research in DUKE-NUS Medical School in Singapore, now published a long-awaited Nature Protocols article describing the laminin-based generation of photoreceptor progenitors from human pluripotent stem cells.

External link to article:
https://www.nature.com/articles/s41596-025-01142-y

About Alder Therapeutics

Alder Therapeutics is a virtual pre-clinical replacement cell therapy development company that is shaping the future of regenerative medicine. Founded in 2022 by seasoned cell therapy and industry experts, the company has two promising allogeneic stem cell therapy programs in the pipeline: one for degenerative eye diseases, and one for chronic heart disease. At the core of the company’s success is the AlderEdge™ platform — a novel approach to cell therapy development that keeps the commercial product in mind from the start for a de-risked route to success.

For more information:

Kristian Tryggvason
CEO
Alder Therapeutics
kristian@aldertx.com